Ostroff: Administration Coming Up To Speed On Planned FDA Guidances
Executive Summary
There’s been a dearth of guidances from US FDA since Donald Trump's inauguration, but the acting FDA commissioner says that simply reflects the new administration catching up on what's in the pipeline. In a speech at FDLI's annual meeting, Stephen Ostroff struck a positive tone.
You may also be interested in...
Gottlieb Becomes FDA Commissioner With Immediate Issues Pending
Confirmation comes with fewest votes of any recent commissioner as FDA faces pressing budget, user-fee and other issues. The Personal Care Products Council welcomed Gottlieb to the post and took the occasion to plug cosmetics industry virtues at a time when legislation is under consideration to update regulations.
Gottlieb Becomes US FDA Commissioner With Immediate Issues Pending
Senate confirmation includes fewest supporting votes for any candidate ever as agency tackles budget, user fees and other issues.
Current FDA Policy Uncertainties Could Yield 'Reverse Impact' Of Support
At FDLI, both US FDA acting Commissioner Stephen Ostroff and BIO’s Kay Holcombe strike note of anticipating positive outcomes for FDA, despite current political and regulatory uncertainties. FDA has been through challenges before, and “we have come through them even stronger," Ostroff assures meeting.